We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Physiomics Plc | PYC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.50 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 18/3/2024 14:23 by le mass du pap Good news this am with a decent sized contract for such a small market cap, surprised it hasn't kicked on yet. The investor presentation sounded solid, with a focus on expanding income streams, securing new clients and contracts and very much pushing on from here. CEO sounded positive and hinted at more news to come with the pipeline for this year up significantly. Therefore I can only assume we have seen the lows? |
Posted at 18/3/2024 10:20 by simonsmithiv Rising on contract award from oversold RSI and tight sma's at the thin end of the squeeze. Investor presentation later today.free stock charts from uk.advfn.com |
Posted at 15/11/2023 13:10 by share14 Well this is the problem, if it was a private consultancy it wouldn't have lasted a few years, let alone almost 2 decades of being listed. There's no pressing need to make the company self sustaining if you can just go cap in hand to investors every few years.Work in a small private firm and you have to do things like this and hustle hard from the get go, not many years down the line when it's getting more difficult to raise funds. A lot of companys on AIM just seem to use shareholders as a way to pay for the business to exist, wasting their investment without returning an actual business that produces profits to them. Why bother if you don't have to? It's quite scandalous how often this happens, because with people like @Laura2022 around continually cheerleading the stock it's just too easy for them to get away with it. Even now it seems they're still doing research projects based on innovation grants instead of focusing on getting the company to breakeven. This is why the cheerleaders need to be challenged and also lse which seems to be doing a great disservice to not only investors but the UK business environment with it's inability to regulate its forum appropriately. It's a symptom of where this Country is right now and how detached from fundamental values it's become. The FCA are asleep at the wheel on this one. |
Posted at 07/10/2023 13:39 by share14 @porkyThey're real lowlifes on lse to get people's posts removed. These people have destroyed these boards which could have been a great way for private investors to help each other. Any time I'm interested in a share I have to wade through hundreds of rampy posts just to get to something interesting. Any time there's a decent poster who's negative about a stock they get called a troll and get their posts removed. Don't expect your post on the PYC board to stick around. I've had dozens removed just for pointing out Laura's figures are make believe. |
Posted at 07/10/2023 04:32 by porky9 @share14Personally, I'm starting to contribute less and less on any of these forums for the exact same reasons as you. I have been active on the Valirx board here and at LSE as my research notes are detailed and I can add value from an evaluation perspective but on all these boards, LSE is far far worse, they offer little value to evaluate and discuss with other investors. Over there they even request removal of posts that don't agree. The moderators then often just delete the entire threads for speed. Almost a total waste of time contributing. What's the point in that?? You cant discuss properly anything about the investee business because the installed cheerleaders just wont have any of it, they just want echo chambers and be comforted by others that think the same way and just there to ramp. Over on LSE earlier the cheerleader @Laura2022 is telling everyone PYC will get £6m from VAL. I mean i ask you, utterly ridiculous. But you are right that nobody will quantify anything i totally agree. Its just how it is, you have to Do your own research frankly, might as well keep it to yourself. @Davevt Thanks for your reply earlier. Everything you say is totally logical. From a quick check on google there are approximately 1,400 Biotech Businesses in the UK that carry our Drug R&D so that is Jim's market. As you say, perfectly feasible for a rep to visit each one in person over 20 years.... These businesses like PYC are clueless about sales and marketing, same over on Valirx, they will go and have a jolly at a trade show and consider that a good use of capital yet there are far more effective ways to reach that audience. My observation is that Jim is a reasonably hard working good guy that is constantly spinning plates, probably talking to the Biotech, working on the tenders through to taking an active part in the drug modeling itself and probably ordering more toilet roll for the bog on his way out the door at night. He is the knowledge. I have seen this so many times in other businesses. Also, In a Biotech financial squeeze, there is clearly less actual new business about and much business on hold so... It looked to me that prior to the drought, they were close to BE i was expecting that to happen and over the last two years the financial squeeze got worse pushing him further back. BUT i do think BE is achievable it's possible which then whist not revolutionary in its own right, at least puts investors minds at rest that they wont be on for yet another cash call. So I come back to the burning question, how do we add exponential growth to this business??. IF cash was available what would he do with it to grow this? Biostats modeling opens another consultancy area hence the new guy but more consultancy work whilst needed, is not the answer IMO. Its all labour intensive and the value of consultancy plays is minimal, like 1x Revenue so the current share price is probably right, 1p to 2p that's our lot. BUT what Jim does have at least is a good installed client base to work from. So to make this business more exciting, what are the expansion areas, clearly AI and product dev like Beyond Blood looks a winner, has anyone here any thoughts??? IF i could think of a fit here frankly i would go to Jim with it. What type of business can be acquired here to help materially advance this play? |
Posted at 24/9/2023 10:46 by intoodeep Investors are forward lookingOthers always look in rear view mirror |
Posted at 23/9/2023 14:06 by intoodeep When the story changes then so should investors mind set. PYC has changed. |
Posted at 12/9/2023 11:38 by davevt ' i like fellow investors to make money Dave but as always they must do their own research. I only recommend folk take a look at a stock if I have a very strong conviction.'The more holders of a share, the less it can go up, because you have more potential sellers. Think about it, if you got everyone in the world to buy in before news, there would be no increase as there would be no buyers. So no, anyone that tries to ramp a share before news to entice people to buy is not believing it will bag. It would be utterly counterproductive. |
Posted at 08/9/2023 10:08 by pwhite73 davevt - "They have to work with clients existing data and results of manual dosing from trials, feed that into the model, and then see if the model can get close to the same dosing, without having to manually do a trial."You've got this back to front. If they're feeding in data from a clinical trial to see if their computer comes up with the same results then that is not computer modelling, that's simply data analysis. The new guidance from the FCA is that they want to see results from computer modelling before they approve clinical trials. share14 - "The business model appears to be obtain money from investors or research bodies" A company can fool private investors indefinitely but they can't fool research grant bodies and if they did certainly not for 20 years on the straight. The problem PYC has always had is economy of scale. There has never been sufficient computer modelling work out their for them to increase staffing levels profitably. It is simply not true there are millions of other larger companies out their doing similar work. In the past regulatory bodies have frowned upon computer models and opined the only real test of drug efficacy is on animals and humans. This is what has changed its now the other way round. In-vivo trials should be a last resort because AI, big data and mathematical modelling should be able to predict clinical outcomes without having to put lives at risk with toxicity. |
Posted at 29/6/2023 14:00 by share14 1347 I feel bad that investors have found themselves in this situation but also livid that several posters tried to shut down people from pointing out that simple truth that the company wasn't making any money and all these rns'es about pipelines, record revenues, and big customers were hot air. That's before you even get to the point where they're announcing new employees, conference visits, and the first project with CRUK debacle.People have taken flack for having the good nature to try and get investors to think about it from a detached position rather than reading and endorsing only positive spin from people that are invested in the company. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
